Soret Pierre-Antoine, Magusto Julie, Housset Chantal, Gautheron Jérémie
Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Inserm, 75012 Paris, France.
Assistance Publique-Hôpitaux de Paris (AP-HP), Hepatology Department, Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, Saint-Antoine Hospital, 75012 Paris, France.
J Clin Med. 2020 Dec 24;10(1):36. doi: 10.3390/jcm10010036.
Non-alcoholic fatty liver disease (NAFLD), including non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), represents the hepatic manifestation of obesity and metabolic syndrome. Due to the spread of the obesity epidemic, NAFLD is becoming the most common chronic liver disease and one of the principal indications for liver transplantation. However, no pharmacological treatment is currently approved to prevent the outbreak of NASH, which leads to fibrosis and cirrhosis. Preclinical research is required to improve our knowledge of NAFLD physiopathology and to identify new therapeutic targets. In the present review, we summarize advances in NAFLD preclinical models from cellular models, including new bioengineered platforms, to in vivo models, with a particular focus on genetic and dietary mouse models. We aim to discuss the advantages and limits of these different models.
非酒精性脂肪性肝病（NAFLD），包括非酒精性脂肪肝（NAFL）和非酒精性脂肪性肝炎（NASH），是肥胖和代谢综合征的肝脏表现形式。由于肥胖症的流行，NAFLD正成为最常见的慢性肝病以及肝移植的主要指征之一。然而，目前尚无获批用于预防NASH发作的药物治疗方法，而NASH会导致肝纤维化和肝硬化。需要开展临床前研究以增进我们对NAFLD病理生理学的了解并确定新的治疗靶点。在本综述中，我们总结了NAFLD临床前模型从细胞模型（包括新型生物工程平台）到体内模型的进展，特别关注基因和饮食小鼠模型。我们旨在讨论这些不同模型的优缺点。
